# Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

> **NCT01072695** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 46 (actual)

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** GS-9256
- **DRUG:** GS-9190
- **DRUG:** Ribavirin
- **DRUG:** Peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT01072695
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-10
- **Final completion:** 2012-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2012-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01072695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01072695, "Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01072695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*